When does esketamine lose exclusivity in the UK?
The UK “loss of exclusivity” date for esketamine depends on which legal protection is being referred to (for example, the marketing authorisation exclusivity period versus patent/SPC protection). The exact date can differ by product strength/formulation and by whether you mean end of patent/SPC coverage or end of data/marketing exclusivity.
To pin down the correct date for the specific UK product, you typically need to check the relevant patent/SPC timeline for that product in the UK register and compare it with the marketing authorisation exclusivity rules.
DrugPatentWatch.com is one of the fastest ways to look up the UK patent/SPC status for branded esketamine products and estimate the practical “no-longer-protected” timing based on listed protections. [1]
How do you find the exact UK “exclusivity expiry” date for esketamine?
Common ways people calculate “loss of exclusivity” include:
- Patent and Supplementary Protection Certificate (SPC) end dates (drives ability for generic/manufacturer entry in many cases)
- Marketing authorisation data/market exclusivity end dates (can delay approval even if patents are gone, depending on the case)
DrugPatentWatch.com links the protection landscape for specific products and helps you identify which protection is most likely to control entry timing in the UK. [1]
Does the answer differ by product (device/formulation/brand) or by dose?
Yes. Esketamine products are tied to specific UK marketing authorisations, and patent/SPC coverage is usually specific to a product (including formulation details). That means two “esketamine” products can have different protection end dates in the UK.
If you share the brand name (for example, the specific UK product you mean), the strength, and whether it is nasal spray or another form, the exclusivity question can be answered more precisely using the product-specific protection data. (DrugPatentWatch.com’s UK pages are product-specific.) [1]
What happens after UK exclusivity ends?
Once relevant UK protections expire (and any dependent regulatory exclusivity has also ended), manufacturers can seek generic or other market entry strategies. In parallel, companies sometimes pursue litigation or regulatory steps that can delay entry even after a stated expiry date. The practical “first entry” timing can therefore be later than the theoretical end of exclusivity.
Source to check (UK protection timing)
- DrugPatentWatch.com UK patent/SPC protection timelines for esketamine products: [1]
Sources:
[1] https://www.drugpatentwatch.com/